Skip to Main Content

Paper Details

PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL.
Eur J Haematol
1
2023
Author NameAffiliation
George TomlinsonUniversity Health Network
  • 1 - 1

Datasets

Release 1.2